Loading
Leads the COG Hodgkin lymphoma committee and the trials bringing brentuximab and nivolumab to children with the disease.
Kara Kelly chairs the Children's Oncology Group Hodgkin lymphoma committee and was study chair of AHOD1331, which showed brentuximab vedotin with chemotherapy improves event-free survival in high-risk paediatric Hodgkin lymphoma and led to the first paediatric approval, and co-leads AHOD2131 testing nivolumab with reduced therapy. Her work focuses on curing children with fewer late effects.
Shares SWOG S1826, SWOG S1826: nivolumab plus AVD chemotherapy versus brentuximab-AVD for advanced Hodgkin lymphoma in adolescents and adults, Brentuximab vedotin, Hodgkin lymphoma.
Shares the tags paediatric, cooperative-group.
Shares SWOG S1826, SWOG S1826: nivolumab plus AVD chemotherapy versus brentuximab-AVD for advanced Hodgkin lymphoma in adolescents and adults, Hodgkin lymphoma, Nivolumab.
Shares Brentuximab vedotin, Hodgkin lymphoma, Nivolumab, Antibody-drug conjugate (ADC) and the tag cooperative-group.
Shares Brentuximab vedotin, Hodgkin lymphoma, Antibody-drug conjugate (ADC) and the tag hodgkin.
Shares the tags paediatric, cooperative-group.
Shares the tags paediatric, cooperative-group.
Shares the tags paediatric, cooperative-group.